Answers are grounded in this paper and cite their sources.
Glepaglutide treatment in patients with SBS with intestinal failure resulted in clinically relevant reductions in PS requirements and was well tolerated. (ClinicalTrials.gov, Number: NCT03690206; ClinicalTrialsRegister.eu, Number: 2017-004394-14.).
No takes yet. Share an insight, caveat, or question.
Jeppesen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: